An Observational Chart Review Study To Describe The Real-World Outcomes And Use Of Avelumab In Combination With Axitinib For Treatment Of Patients With aRCC In The UK

Pfizer130 enrolled

Overview

An observational chart review study to describe the real-world outcomes and use of avelumab in combination with axitinib for treatment of patients with advanced renal cell carcinoma in the United Kingdom.

Study Type

OBSERVATIONAL

Enrollment

130

Conditions

Advanced Renal Cell Carcinoma

Interventions

avelumabDRUG

as provided in real world setting

axitinibDRUG

as provided in real world settings

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion criteria * Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study: * Patients with a documented diagnosis of aRCC. * Patients aged ≥18 years old at the index event date. * Patient initiated on treatment with avelumab in combination with axitinib ( ≥1 dose) on or after 1st August 2019. Exclusion criteria * Patients meeting any of the following criteria will not be included in the study: * Patients who received avelumab in combination with axitinib as part of a clinical trial * Patients initiated on avelumab in combination with axitinib less than 12 months from the end of data collection. * Patients who are known to have opted out of participation in any research

Locations (1)

Pfizer Ltd

Sandwich, Kent, United Kingdom

Outcomes

Primary Outcomes

Objective response (OR)

"Percentage of participants with objective response based assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short aixs was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. "

Time frame: August 2019 through July 2023

Overall Survival (OS)

Time in weeks or months from randomization (or the start of study treatment for non-randomized studies) to date of death due to any cause. OS was calculated as (the death date or last known alive date (if death date unavailable) minus the date of randomization (or first dose of study medication for non-randomized studies) plus 1) divided by 7 or 30.44 if in months.

Time frame: August 2019 through July 2023

Progression Free Survival (PFS)

Median time from the first dose of study treatment to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first. PFS calculated as (Weeks) = (first event date minus first dose date plus 1) divided by 7

Time frame: August 2019 through July 2023

Duration of Response (DoR)

Median duration (50%) of tumor response for a subgroup of participants with objective disease response: who have not progressed or died due to any cause; with a response and subsequent progression or death due to any cause for DR. DR defined as time from start of first documented objective tumor response \[Complete Response (CR) or Partial Response (PR)\] to first documented objective tumor progression or death due to any cause, whichever occurs first. DR calculated as (Weeks) = (the end date for DR minus first subsequent confirmed CR or PR plus 1) divided by 7.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.